Genmab — November 2022
-
The license agreement states that the milestone payments and royalties are paid on a licensed product-by-licensed product basis, and for each licensed product, royalty payments shall commence on the date of the first commercial sale of such licensed product and expiring on the later of 13 years thereafter or the expiration of relevant patents, Harrison tells investors in a research note. He says the key issue is whether Genmab is entitled to additional milestone payments and a new 13-year
-
royalty term from Darzalex Faspro's first commercial sale date. Harrison views Genmab's risk/reward as favorable into the 2023 ruling.
-
Okay, thanks for the clarification EL. Looks quite promissing then. But but but…
-
23xAnalytiker target og revenue forecast 2023 fra tradingview https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/108171_Skaermbillede_2022_11_29_150015_trading_view.jpg
-
November 29, 2022 04:25 PM Eastern Standard Time
DUBLIN--(BUSINESS WIRE)--The Board of Horizon Therapeutics plc (Nasdaq: HZNP) (“Horizon” or the “Company”) confirms that it is engaged in highly preliminary discussions with Amgen Inc., Janssen Global Services, LLC and Sanofi (each a "Possible Offeror") which may or may not lead to an offer being made for the entire share capital of the Company. There can be no certainty that any offer will be made for the Company. -
Godmorgen.
-
Godmorgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind